HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Parlux

This article was originally published in The Rose Sheet

Executive Summary

Second quarter sales are expected to be up 74% to approximately $39 mil.-$40 mil., bolstered by international rollout of Guess? and Maria Sharapova fragrances as well as new Paris Hilton scent, Just Me, firm announces Oct. 6. Company's Perry Ellis fragrance portfolio will be strengthened by the launch of Perry 18 next summer, Parlux adds. Firm also reiterates previously reported fiscal year sales guidance of $190 mil.-$210 mil. Parlux will release final Q2 results the first week in November...

You may also be interested in...



Parlux

Final second quarter results, originally expected the first week of November, will not be released until Nov. 11 due to a power outage in Parlux' Florida-based office and distribution facility caused by Hurricane Wilma, fragrance marketer announces Nov. 1. The company has resumed normal operations and expects to meet previous guidance and holiday commitments. Second quarter sales are expected to be up 74% to approximately $39 mil.-$40 mil., company reported Oct. 6 (1"The Rose Sheet" Oct. 10, 2005, In Brief). Firm anticipates restarting stock buyback program as the hurricane "unreasonably depressed" stock market price. Parlux markets scents including Guess? and Just Me by Paris Hilton...

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013419

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel